Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2015
March 2015, Vol 6, No 2
March 2015, Vol 6, No 2
Vosaroxin, a Quinolone Derivative, Extends Survival in Older Patients with Acute Myeloid Leukemia
By
Wayne Kuznar
Hematologic Malignancies
,
Leukemia
March 2015, Vol 6, No 2
An investigational first-in-class anticancer quinolone derivative, vosaroxin, extended median overall survival (OS) when used with cytarabine (Cytosar-U) in a phase 3 clinical trial of patients with relapsed or refractory acute myeloid leukemia (AML), although the difference was not significant.
Read Article
Blinatumomab Immunotherapy Attacks Minimal Residual Disease in ALL, Leads to High Rates of Complete Response
By
Wayne Kuznar
Hematologic Malignancies
,
Leukemia
March 2015, Vol 6, No 2
San Francisco, CA—In patients with acute lymphoblastic leukemia (ALL), assessment of minimal residual disease (MRD) is increasingly used to evaluate response to treatment. An antibody that recruits the body’s T-cells to attack MRD in patients with ALL whose disease is in remission can prevent full relapse.
Read Article
Foreign-Trained Physicians Less Likely to Screen for Cancer, Especially Among Immigrant Populations
By
Rosemary Frei, MSc
Quality Care
,
Policies & Guidelines
March 2015, Vol 6, No 2
Screening for cancer is suboptimal among some immigrant populations, especially those whose primary care physicians are trained in foreign countries, according to results of a new study of primary care practices in Canada; specifically, women from South Asia whose family physicians were trained in South Asia were less likely to be screened for cervical cancer than nonimmigrant women whose physicians were not immigrants.
Read Article
Localized Renal Cancer Surgery Associated with Substantial Costs from Lost Productivity
By
Phoebe Starr
Genitourinary Cancers Symposium
March 2015, Vol 6, No 2
Orlando, FL—The total costs of renal surgery are not limited to hospitalization but accrue long after discharge. According to data presented at the 2015 Genitourinary Cancers Symposium, most patients took more than 30 days off work after radical or partial nephrectomy, with the average estimated wages lost to unpaid time exceeding $10,000.
Read Article
Debate on PSA Prostate Cancer Screening Redux
By
Phoebe Starr
Genitourinary Cancers Symposium
,
Prostate Cancer
,
Solid Tumors
March 2015, Vol 6, No 2
Orlando, FL—A new retrospective study of 87,562 men diagnosed with prostate cancer between January 2005 and June 2013 show that the incidence of prostate cancer and men with prostate-specific antigen (PSA) >10 decreased gradually between 2005 and 2011. However, the incidence of high-risk prostate cancer at diagnosis increased annually by 3% between 2011 and 2013, totaling 6%. This increase could lead to an additional 1400 prostate cancer deaths 10 years later.
Read Article
History of Testicular Cancer Increases Risk for Aggressive Prostate Cancer Later on
By
Phoebe Starr
Genitourinary Cancers Symposium
March 2015, Vol 6, No 2
Orlando, FL—Previous studies have shown that a history of testicular cancer increases the risk for developing prostate cancer. A new study presented at the 2015 Genitourinary Cancers Symposium shows, for the first time ever, a link between a history of testicular cancer and an increased likelihood of intermediate- and high-risk prostate cancer sometime in the future.
Read Article
Caution: Active Surveillance Ill Advised in Men with Intermediate-Risk Prostate Cancer
By
Phoebe Starr
Genitourinary Cancers Symposium
March 2015, Vol 6, No 2
Orlando, FL—Active surveillance is sometimes used as management strategy in patients with intermediate-risk prostate cancer, especially in older, sicker men with short life expectancy. A new study validates the use of active surveillance for men with low-risk prostate cancer but provides sobering data regarding this type of management for those with intermediate-risk prostate cancer. The study results were presented at the 2015 Genitourinary Cancers Symposium.
Read Article
Regorafenib in Metastatic Colorectal Cancer: High Cost with Little Benefit
By
Chase Doyle
Economics & Value
,
Economics of Cancer Care
March 2015, Vol 6, No 2
San Francisco, CA—According to a recent cost-effectiveness analysis, third-line therapy with regorafenib (Stivarga) in patients with previously treated metastatic colorectal cancer (CRC) far exceeded accepted willingness-to-pay thresholds based on incremental cost-effectiveness ratio (ICER) and quality-adjusted life-years (QALYs). Presented at the 2015 Gastrointestinal Cancers Symposium, the results showed that regorafenib provided an additional 0.04 QALYs, at a cost of $39,391.
Read Article
Preventing Relapse in Myeloma Carries Economic Benefits, Reduces Overall Costs
By
Dana Taylor
Economics & Value
,
Economics of Cancer Care
March 2015, Vol 6, No 2
San Francisco, CA—In what is believed to be the first economic analysis of disease progression of patients with myeloma, researchers found that in patients with newly diagnosed myeloma, the monthly costs are reduced by 68% between the first 4 months through 18 months, but they then rise steeply when the disease relapses. The data were presented at the 2014 American Society of Hematology meeting.
Read Article
Value Propositions - March 2015
Value Propositions
,
Value Peer-spectives
March 2015, Vol 6, No 2
Read Article
Page 2 of 3
1
2
3
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma